A. A. Druzhinina has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Tirzepatide and Semaglutide in Type 2 Diabetes Mellitus and Obesity: A Comparative Assessment of Efficacy and Safety (Review)

    by E. M. Eliseeva, A. A. Druzhinina, A. A. Chistokhina, Е. М. Елисеева, А. А. Дружинина, А. А. Чистохина

    INTRODUCTION. In the last two decades, pharmacotherapy for obesity and type 2 diabetes mellitus has evolved toward drugs that target the incretin system, such as semaglutide, a glucagon-like peptide-1 (GLP-1) receptoragonist, and tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Both drugs are highly effective in reducing body weight and improving glycemic control, but differences in safetyprofiles necessitate comparative analysis for personalized treatment selection. AIM. Comparative assessment of the efficacy and safety of tirzepatide and semaglutide in type 2 diabetes mellitus and obesity based on clinical trial data and post-registration pharmacovigilance, identifying key differencesin the spectrum and frequency of adverse drug reactions to develop a strategy for post-registration safety monitoring. DISCUSSION. In clinical trials, tirzepatide was associated with greater reductions in glycated hemoglobin (in SURPASS-2, the difference ranged from –0.15% to –0.44%) and body weight (in SURMOUNT-2, –14.7% vs. –9.6%in STEP-2) compared with semaglutide; real-world data are consistent with these findings. According to pharmacovigilance databases (VigiBase, FAERS), gastrointestinal disorders are the most frequently reported adversedrug reactions for both agents (up to 70%), with comparable risks of serious gastrointestinal events. Tirzepatide is associated with a higher risk of vomiting, diarrhea, and constipation, whereas specific signals and adverse drugreactions have been identified for semaglutide, including acute kidney injury, nonarteritic anterior ischemic optic neuropathy, depressive disorders, and dysesthesia. CONCLUSIONS. Tirzepatide and semaglutide are effective in reducing glycated hemoglobin levels and body weight (more pronounced for tirzepatide). The safety profiles of the drugs are generally comparable, but differences have been identified in the spectrum of rare adverse drug reactions. Due to the heterogeneity of the design and limited sample sizes, the results of studies on the effects on the thyroid gland, bone tissue, and fertilityrequire confirmation in long-term prospective studies. A comprehensive approach to safety monitoring is needed, combining differentiated risk monitoring for tirzepatide and semaglutide.

  • Open Access

    Therapeutic Potential of Myo-Inositol in Male Infertility: Correction of Spermatogenesis Parameters and Oxidative Stress (Review)

    by S. M. Giulakhmedova, A. A. Druzhinina, O. S. Alyautdina, E. M. Eliseeva, A. A. Chistokhina

    INTRODUCTION. Male infertility, in particular reproductive system deficiency, is often associated with oxidative stress. Myo-inositol antioxidant properties are essential for various biochemical and cellular processes in spermatozoa; for example, they contribute to mitochondrial function and sperm motility. This creates an opportunity to use inositol in the complex infertility treatment of various aetiology, including oligoasthenoteratozoospermia, asthenozoospermia, and in assisted reproductive technologies.AIM. This study aimed to evaluate the possibility and effectiveness of using inositol for spermatogenesis restoration in male reproductive dysfunction caused by oxidative stress.DISCUSSION. Oxidative stress damages sperm cell membrane, causes mitochondrial dysfunction, and affects DNA. Studies show that myo-inositol positively impacts spermatogenesis due to its antioxidant properties and activation of mitochondrial metabolism. It promotes ATP production, reduces oxidative damage markers, decreases DNA fragmentation and improves sperm morphology. Moreover, myo-inositol increases cellular testosterone, optimises actin — globulin binding, thus enhancing sperm motility, and modulates intracellular calcium concentrations necessary for oxidative metabolism and ATP synthesis. Clinical studies have shown that inositol increases overall sperm motility by 20–30%; progressive motility — up to 40%; fertilisation rate — by 10–15%, and reduces DNA fragmentation by 3–5%. Myo-inositol used for sperm cryopreservation reduces reactive oxygen and apoptosis, maintains mitochondrial membrane potential, and increases oxidative phosphorylation efficiency by 6–15%.CONCLUSIONS. Myo-inositol is a promising therapeutic compound for treating male infertility of various aetiology, including oligoasthenoteratozoospermia, asthenozoospermia, and for preparing sperm in assisted reproductive technologies. Also, due to its antioxidant properties, myo-inositol can be recommended in suspected or confirmed oxidative damage to sperm. However, large controlled trials are needed to confirm positive effect of myo-inositol on male reproductive function.

  • Open Access

    Analysis of Errors Identified during Regulatory Review of Risk Management Plans Submitted as Part of Registration Dossiers

    by A. O. Lovkova, S. M. Gyulakhmedova, A. A. Druzhinina, A. A. Nekipelova

    Scientific relevance. On 6 December 2022, an updated version of the Rules for Good Pharmacovigilance Practice of the Eurasian Economic Union (EAEU GVP) came into force. The greatest changes were made to the requirements for pharmacovigilance documents, particularly the risk management plan (RMP). In practice, the changed EAEU GVP has resulted in multiple errors, creating the need to thoroughly analyse their structure and causes and to develop recommendations for their prevention.Aim. This study aimed to identify, analyse, and collate inconsistencies between the information submitted by marketing authorisation holders in their RPMs and the updated EAEU GVP requirements.Materials and methods. The Scientific Centre for Expert Evaluation of Medicinal Products analysed 50 RMPs received after 6 December 2022 as part of registration dossiers aimed to support marketing authorisation applications and/or align the registration dossiers with the EAEU requirements.Results. The errors made by applicants when preparing RMPs were categorised according to their influence on the interpretation of a medicinal product’s safety profile. The errors leading to incorrect safety profile interpretations were considered type 1 errors (63% of the cases). The errors affecting the perception of the RMP but not the interpretation of the safety profile (e.g., grammatical errors, notes and comments by applicants, incorrect translation of terms) were deemed type 2 errors (37% of the cases). The majority of EAEU GVP noncompliance cases were detected in Part II of the RMP, the section providing the most information on the safety profile of a medicinal product.Conclusions. There are several ways to improve the quality of RMP preparation. The information included in the RMP should be compared with the information provided in the registration dossier. The RMP should be incorporated into the integrated pharmaceutical quality system according to the requirements of good practices.A responsible employee of the marketing authorisation holder’s quality assurance system should control the final RMP version. Employees of pharmacovigilance departments should receive regular training.

  • Open Access

    Safety of Antibacterial and Antiprotozoal Medicinal Products

    by E. V. Shubnikova, T. M. Bukatina, A. A. Druzhinina, E. O. Zhuravleva, G. V. Kutekhova, N. Yu. Velts, Н. Ю. Вельц

    The experts of the Scientific Centre for Expert Evaluation of Medicinal Products analysed administrative decisions of foreign regulatory authorities on the recalls of antibacterial and antiprotozoal medicinal products and/or the need for labelling updates due to changes in the safety profile. The analysis revealed 16 decisions containing information on the following medicines registered in Russia: ertapenem, сeftriaxone, cefazolin, аmoxicillin, сefoperazone+sulbactam, piperacillin+tazobactam, сlindamycin, teicoplanin, rifampin, co-trimoxazole, hydroxychloroquine.


  • Open Access

    Ivermectin: Evaluation of Efficacy and Safety in COVID-19

    by E. V. Shubnikova, N. A. Susekova, T. M. Bukatina, M. S. Galenko, A. A. Druzhinina

    The search for an effective and safe COVID-19 therapy involves, among other things, assessment of efficacy of medicines already used for the treatment of other diseases, and having potential antiviral activity against SARS-CoV-2. The relevance of the presented study stems from ambiguous data on the off-label use of the antiparasitic medicine ivermectin for the treatment of COVID-19 patients. The aim of the study was to analyse ivermectin efficacy and safety for COVID-19 treatment, as reflected in the scientific literature. Ivermectin, an antiparasitic medicine from the group of macrocyclic lactones produced byStreptomyces avermitilis, stimulates release of the inhibitory neurotransmitter gamma-aminobutyric acid, which leads to impaired transmission of nerve impulses, paralysis and death of parasites. The results of preclinical studies show ivermectin’s inhibitory activity against a number of RNA and DNA viruses, including SARS-CoV-2. The results of ivermectin clinical studies are ambiguous: a number of studies demonstrated a positive effect on the condition of COVID-19 patients, however, there is currently no convincing evidence of the validity and efficacy of ivermectin use for the prevention and treatment of COVID-19 patients. The safety profile of ivermectin is relatively favourable. Large randomised controlled trials are needed to fully assess the feasibility of using ivermectin in COVID-19.


  • Open Access

    Drug Safety Monitoring Information

    by E. V. Shubnikova, E. O. Zhuravleva, N. Yu. Velts, P. M. Giulakhmedova, A. A. Druzhinina, Н. Ю. Вельц

    Analysis of administrative decisions of foreign regulatory authorities on the recall of medicines and/or the need for changes in the instructions for their medical use due to changes in the safety profile, conducted by experts of the Scientific Centre for Expert Evaluation of Medicinal Products revealed 19 administrative decisions. These decisions contained information on the following medicines registered in Russia: amikacin, tobramycin, gentamicin, neomycin, ciprofloxacin, delafloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin, prulifloxacin, rufloxacin, сeftriaxone, ceftaroline, rifapentine, tigecycline, bacitracin, ertapenem, daptomycin, erythromycin, fosfomycin, ampicillin+sulbactam, chloroquine, hydroxychloroquine.